nature

当前位置: Nature » 神经科学 » 正文

Sci Rep:英国学者揭示蘑菇或能改变抑郁症患者大脑

摘要 : 2017年10月13日,国际学术权威刊物自然出版集团旗下子刊《Scientific Reports》杂志在线发表了英国伦敦帝国学院的Robin Carhart-Harris研究组的一篇研究论文,研究发现神奇蘑菇中发现的一种迷幻化合物——裸盖菇素或许能帮助重新设定大脑中同抑郁症相关的神经回路的活动。

2017年10月13日,国际学术权威刊物自然出版集团旗下子刊《Scientific Reports》杂志在线发表了英国伦敦帝国学院的Robin Carhart-Harris研究组的一篇研究论文,研究发现神奇蘑菇中发现的一种迷幻化合物——裸盖菇素或许能帮助重新设定大脑中同抑郁症相关的神经回路的活动。

一直以来,神奇蘑菇的热衷者认为,该药物诱导产生深沉感觉的能力或许能被用于疾病的治疗。同时,大脑成像研究证实,裸盖菇素靶向的是在抑郁症中过度活跃的大脑区域。

之前Robin Carhart-Harris和同事开展了利用裸盖菇素治疗抑郁症的首次临床试验,并且获得了一些振奋人心的结果。虽然此次试验仅涉及12人并且没有对照组,但该团队发现,经过两个疗程的裸盖菇素辅助精神疗法,所有志愿者的症状均有所减轻。如今,Carhart-Harris和团队成员发现,裸盖菇素似乎能引发抑郁症患者大脑的改变。此项研究涉及19人。和此前研究一样,受试者患有抑郁症但传统治疗对其无效。每名志愿者间隔7天分别服用10毫克和25毫克剂量的裸盖菇素。大脑扫描显示,在服用该药物后,大脑某些区域的活动开始减少。这些区域包括在处理压力和恐惧方面起到一定作用的杏仁核。参与者报告称,他们的心情立即有了改善并且最长持续了5周。

“我们首次证实,在对传统疗法未作出任何反应后,接受裸盖菇素治疗的抑郁症患者在大脑活动方面出现了明显改变。”Carhart-Harris介绍说。

“这是关于裸盖菇素可能对最顽固的抑郁症产生疗效的进一步证据。”来自伦敦国王学院的Paul Morrison表示,“这个领域的进展是精神病学优先关注的重点。一些人会遭受抑郁症的多年折磨,而该疾病似乎能抵抗所有标准疗法。”

不过,Carhart-Harris团队警告说,人们不应当尝试用裸盖菇素药物进行自我治疗。

原文链接:

Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms

原文摘要:

Psilocybin with psychological support is showing promise as a treatment model in psychiatry but its therapeutic mechanisms are poorly understood. Here, cerebral blood flow (CBF) and blood oxygen-level dependent (BOLD) resting-state functional connectivity (RSFC) were measured with functional magnetic resonance imaging (fMRI) before and after treatment with psilocybin (serotonin agonist) for treatment-resistant depression (TRD). Quality pre and post treatment fMRI data were collected from 16 of 19 patients. Decreased depressive symptoms were observed in all 19 patients at 1-week post-treatment and 47% met criteria for response at 5 weeks. Whole-brain analyses revealed post-treatment decreases in CBF in the temporal cortex, including the amygdala. Decreased amygdala CBF correlated with reduced depressive symptoms. Focusing on a priori selected circuitry for RSFC analyses, increased RSFC was observed within the default-mode network (DMN) post-treatment. Increased ventromedial prefrontal cortex-bilateral inferior lateral parietal cortex RSFC was predictive of treatment response at 5-weeks, as was decreased parahippocampal-prefrontal cortex RSFC. These data fill an important knowledge gap regarding the post-treatment brain effects of psilocybin, and are the first in depressed patients. The post-treatment brain changes are different to previously observed acute effects of psilocybin and other ‘psychedelics’ yet were related to clinical outcomes. A ‘reset’ therapeutic mechanism is proposed.

来源: Scientific Reports 浏览次数:0

热门文章TOP

RSS订阅 - 填写您的邮件地址,订阅我们的精彩内容: - 网站地图
网站联系电话:020-87540820 备案号:粤ICP备11050685号-8 增值电信业务经营许可证:粤B2-20120479
©2011-2015 生物帮 All rights reserved.